Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,cash,totalCurrentLiabilities,totalCurrentAssets,accountsPayable,otherCurrentLiab,otherCurrentAssets,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,market,shortName,exchange,marketState,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,exchangeDataDelayedBy,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GLSI,29731829.0,12895800,281977,,-597008,,-597008,318629,0,-600606,-600606,,,,,,0,0,600606,0,3598,,-597008,-597008,15324.0,59408267.0,673122.0,29747153.0,30420275.0,12847.0,-29673961.0,30404951.0,673122.0,30404951.0,609274.0,,,-120000,-275154,2272846,22784,2548000,1744576,-528270,903,165051,29731829.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,43.75,1630526403,3.7299995,42.0,45.2739,41.21,125639,40.73457,3.0154305,0.074026324,37.419853,6.330147,0.16916546,564191232,15,America/New_York,EDT,False,False,USD,us_market,"Greenwich LifeSciences, Inc.",NCM,PREPRE,2,0.5714286,1630540373,44.0,0.25,9.320339,41.21 - 45.2739,40.02,0.0,0.0,13,22,finmb_653283398,NasdaqCM,"Greenwich LifeSciences, Inc.",USD,88503,23357,40.488,12.412017,3.262 - 158.07,-114.32001,-0.7232239,3.262,158.07,0,-14400000,,,,158.07,3.26,40.73,37.42,88.5k,23.36k,12.9M,,2.88M,74.44%,2.14%,136.03k,1.49,3.36%,1.05%,122.91k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-9.11%,-15.64%,,,,,-2.22M,-2.22M,,,30.4M,2.36,,,45.17,,-1.68M,-853.25k,Value,77477,Healthcare,1,"Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.",Stafford,832 819 3232,TX,1609372800,United States,http://greenwichlifesciences.com,86400,Building 14,Biotechnology,3992 Bluebonnet Drive
t-1,GLSI,27614883.0,12895800,598880,,-1151026,,-1151026,552978,0,-1151858,-1151858,,,,,,0,0,1151858,0,832,,-1151026,-1151026,16227.0,56695359.0,1045492.0,27631110.0,28676602.0,12704.0,-29076953.0,28660375.0,1045492.0,28660375.0,710971.0,,,-107550,-360000,23599000,-60340,23959000,22446038,-1152962,903,165051,27614883.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,43.75,1630526403,3.7299995,42.0,45.2739,41.21,125639,40.73457,3.0154305,0.074026324,37.419853,6.330147,0.16916546,564191232,15,America/New_York,EDT,False,False,USD,us_market,"Greenwich LifeSciences, Inc.",NCM,PREPRE,2,0.5714286,1630540373,44.0,0.25,9.320339,41.21 - 45.2739,40.02,0.0,0.0,13,22,finmb_653283398,NasdaqCM,"Greenwich LifeSciences, Inc.",USD,88503,23357,40.488,12.412017,3.262 - 158.07,-114.32001,-0.7232239,3.262,158.07,0,-14400000,,,,158.07,3.26,40.73,37.42,88.5k,23.36k,12.9M,,2.88M,74.44%,2.14%,136.03k,1.49,3.36%,1.05%,122.91k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-9.11%,-15.64%,,,,,-2.22M,-2.22M,,,30.4M,2.36,,,45.17,,-1.68M,-853.25k,Value,77477,Healthcare,1,"Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.",Stafford,832 819 3232,TX,1609372800,United States,http://greenwichlifesciences.com,86400,Building 14,Biotechnology,3992 Bluebonnet Drive
t-2,GLSI,4640955.0,12895800,158031,,-256865,,-256865,98834,0,-256865,-256865,,,,,,0,0,256865,0,0,,-256865,-256865,17130.0,32572042.0,1615962.0,4658085.0,6274047.0,11970.0,-27925927.0,6214337.0,1615962.0,6256917.0,800219.0,42580.0,42580.0,15000,-360000,6207502,75911,6207502,6207502,-1152962,903,165051,4640955.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,43.75,1630526403,3.7299995,42.0,45.2739,41.21,125639,40.73457,3.0154305,0.074026324,37.419853,6.330147,0.16916546,564191232,15,America/New_York,EDT,False,False,USD,us_market,"Greenwich LifeSciences, Inc.",NCM,PREPRE,2,0.5714286,1630540373,44.0,0.25,9.320339,41.21 - 45.2739,40.02,0.0,0.0,13,22,finmb_653283398,NasdaqCM,"Greenwich LifeSciences, Inc.",USD,88503,23357,40.488,12.412017,3.262 - 158.07,-114.32001,-0.7232239,3.262,158.07,0,-14400000,,,,158.07,3.26,40.73,37.42,88.5k,23.36k,12.9M,,2.88M,74.44%,2.14%,136.03k,1.49,3.36%,1.05%,122.91k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-9.11%,-15.64%,,,,,-2.22M,-2.22M,,,30.4M,2.36,,,45.17,,-1.68M,-853.25k,Value,77477,Healthcare,1,"Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.",Stafford,832 819 3232,TX,1609372800,United States,http://greenwichlifesciences.com,86400,Building 14,Biotechnology,3992 Bluebonnet Drive
t-3,GLSI,-1477617.0,12895800,150804,,-210430,,-210430,59626,0,-210430,-210430,,,,,,0,0,210430,0,0,,-210430,-210430,18033.0,26200864.0,1738283.0,-1459584.0,280680.0,8614.0,-27669062.0,6835.0,1738283.0,262647.0,766916.0,255812.0,255812.0,0,-360000,6207502,35586,6207502,6207502,-1152962,901,173943,-1475636.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,43.75,1630526403,3.7299995,42.0,45.2739,41.21,125639,40.73457,3.0154305,0.074026324,37.419853,6.330147,0.16916546,564191232,15,America/New_York,EDT,False,False,USD,us_market,"Greenwich LifeSciences, Inc.",NCM,PREPRE,2,0.5714286,1630540373,44.0,0.25,9.320339,41.21 - 45.2739,40.02,0.0,0.0,13,22,finmb_653283398,NasdaqCM,"Greenwich LifeSciences, Inc.",USD,88503,23357,40.488,12.412017,3.262 - 158.07,-114.32001,-0.7232239,3.262,158.07,0,-14400000,,,,158.07,3.26,40.73,37.42,88.5k,23.36k,12.9M,,2.88M,74.44%,2.14%,136.03k,1.49,3.36%,1.05%,122.91k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-9.11%,-15.64%,,,,,-2.22M,-2.22M,,,30.4M,2.36,,,45.17,,-1.68M,-853.25k,Value,77477,Healthcare,1,"Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.",Stafford,832 819 3232,TX,1609372800,United States,http://greenwichlifesciences.com,86400,Building 14,Biotechnology,3992 Bluebonnet Drive
